ISSAR Pharma


ISSAR’S second New Chemical Entity,
a peptide-based drug, Xylentra®,
developed for the treatment of burn
wounds and microbial infections.

ISSAR offers standardized and uncompromised quality of Peptide Drugs based on the  project needs. Our company’s research and development is in accordance with the ICH and USP guidelines. We are cGMP approved and equipped with a US-FDA-compliant manufacturing facility.

The Quality support is initiated and adhered to at every stage of drug development process and continued even after the product is delivered.

Our Quality services includes

• Recognition of quality needs when generating a quote.
• Confirming an order.
• Designing the most suitable manufacturing process.
• Controlling product quality at each production step.
• Informing clients in a timely fashion.
• Conducting finished product testing.
• Generating the Certificate of Analysis (CoA).
• Releasing the final product.

Quality support further continues after product release in the form of Stability studies and Regulatory filing assistance.

What are peptides?

• Peptides are naturally occurring, small biological molecules made of short chains of amino acids linked by a peptide bond.

• Peptides typically contain 2-50 amino acids, therefore easily absorbed by the body when compared to proteins which are larger in size.

• Peptides contain amino acid sequences which control and coordinate all cellular functions and intracellular communication.

• Peptides are highly target specific, safe and non-toxic as their degradation products only involve simple amino acids.

Xylentra® contains an active drug substance called Genopep®. Genopep® is a 23 amino acid peptide composed of three specific amino acids known as Alanine (A), Phenylalanine (F) and Lysine (K) comprising the peptide sequence. The counter ion associated with cationic side chains in the peptide is the acetate ion.

It is available in the form of Xylentra® cream (Genopep 0.05%). Regular use of the cream results in:

• Stimulation of fibroblast and keratinocyte growth factors
• Potent wound healing
• Broad spectrum anti-microbial activity 
• Prevention of scar 

The Xylentra® cream is formulated to spread easily without adherence to the skin. Xylentra® effectively controls the infection(s) while treating burn wounds without producing any adverse effects.

Designed as a broad spectrum anti-bacterial for the treatment of burn wounds.

• Use this medicine according to the dosage prescribed by your doctor.
• Use for 4 weeks or till the day of complete wound healing or infection

How to use Xylentra® cream

• The measured quantity of cream should be applied to the affected area.
• If dressing is required, the cream should be covered with Plain / Vaseline gauze.
• The cream should be applied to the affected area once in a day, generally for a period of 28 days.
• After the dosing period, the cream can be gently rinsed off using saline/water.

How Xylentra® cream works

When Xylentra® is applied on the burn wound area, it stimulates fibroblast and keratinocyte growth factors and inhibits the growth of the commonly occurring bacteria including the most resistant forms. Thus, it controls infection without producing side effects.

Xylentra® cream provides an optimum physiological environment for regeneration, repair, and spontaneous healing without further damage to the viable tissues.

The Xylentra® cream is formulated to spread easily without adhering to the skin. Xylentra® effectively controls the infection(s) while treating burn wounds without producing any adverse effects.

• This medicine is only for external use and topical application.

• It should be sold by retail on the prescription of registered medical practitioner only.

• Xylentra® cream should not be prescribed to patients with a history of hypersensitivity to it.

• Adequate human data on use during pregnancy is not available.

• Keep out of reach of children.

“GENOPEP”, a Topical Cream in the Treatment of Burn Wounds
Disclaimer: The data contained in this website is intended for general reference only. It may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country and it should be noted that, over time, currency and completeness of the data may change. For updated information, please contact the Company. This data should not be used to diagnose, treat, cure or prevent any disease without the professional advice of a Registered Medical Practitioner, and does not replace medical advice or a thorough medical examination. Registered Medical Practitioners should use their independent professional judgement in checking the symptoms, diagnosing & suggesting the appropriate line of treatment for patients. ISSAR pharmaceuticals is not in any way influencing, propagating or inducing anyone to buy or use ISSAR products. ISSAR accepts no liability for any loss, damage or compensation claims in connection with any act or omission by anyone based on information contained in or derived through use of this website. Duplication of or copying any data requires prior permission of the copyright holder. For adverse event reporting with respect to products of ISSAR, kindly email us at